In silico design and optimization of selective membranolytic anticancer peptides

Abstract Membranolytic anticancer peptides represent a potential strategy in the fight against cancer. However, our understanding of the underlying structure-activity relationships and the mechanisms driving their cell selectivity is still limited. We developed a computational approach as a step tow...

Full description

Saved in:
Bibliographic Details
Main Authors: Gisela Gabernet, Damian Gautschi, Alex T. Müller, Claudia S. Neuhaus, Lucas Armbrecht, Petra S. Dittrich, Jan A. Hiss, Gisbert Schneider
Format: article
Language:EN
Published: Nature Portfolio 2019
Subjects:
R
Q
Online Access:https://doaj.org/article/b8f8603aa1a34be985c452e189d9f671
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Membranolytic anticancer peptides represent a potential strategy in the fight against cancer. However, our understanding of the underlying structure-activity relationships and the mechanisms driving their cell selectivity is still limited. We developed a computational approach as a step towards the rational design of potent and selective anticancer peptides. This machine learning model distinguishes between peptides with and without anticancer activity. This classifier was experimentally validated by synthesizing and testing a selection of 12 computationally generated peptides. In total, 83% of these predictions were correct. We then utilized an evolutionary molecular design algorithm to improve the peptide selectivity for cancer cells. This simulated molecular evolution process led to a five-fold selectivity increase with regard to human dermal microvascular endothelial cells and more than ten-fold improvement towards human erythrocytes. The results of the present study advocate for the applicability of machine learning models and evolutionary algorithms to design and optimize novel synthetic anticancer peptides with reduced hemolytic liability and increased cell-type selectivity.